Lake Street Capital Cuts Evaxion A/S (NASDAQ:EVAX) Price Target to $9.00

Evaxion A/S (NASDAQ:EVAX) had its price objective lowered by Lake Street Capital from $11.00 to $9.00 in a research report report published on Monday,Benzinga reports. The firm currently has a buy rating on the stock.

EVAX has been the topic of several other research reports. Maxim Group assumed coverage on Evaxion A/S in a report on Thursday, February 19th. They set a “buy” rating and a $10.00 target price on the stock. HC Wainwright restated a “buy” rating and issued a $16.00 price target on shares of Evaxion A/S in a research note on Monday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Evaxion A/S in a research report on Friday, January 9th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $11.00.

Evaxion A/S Stock Up 8.1%

Shares of EVAX stock opened at $3.87 on Monday. The firm’s fifty day moving average price is $3.83 and its two-hundred day moving average price is $4.62. The company has a current ratio of 5.85, a quick ratio of 5.85 and a debt-to-equity ratio of 0.41. Evaxion A/S has a 1 year low of $1.20 and a 1 year high of $12.15. The firm has a market capitalization of $32.28 million, a P/E ratio of -2.93 and a beta of 0.28.

Evaxion A/S (NASDAQ:EVAX) last posted its quarterly earnings data on Thursday, March 5th. The company reported $0.30 EPS for the quarter. On average, equities analysts predict that Evaxion A/S will post -0.15 EPS for the current fiscal year.

Hedge Funds Weigh In On Evaxion A/S

A number of institutional investors have recently bought and sold shares of the business. Northwestern Mutual Wealth Management Co. bought a new position in shares of Evaxion A/S during the 4th quarter worth approximately $38,000. Wesbanco Bank Inc. bought a new stake in Evaxion A/S in the 4th quarter valued at $48,000. Finally, SmartHarvest Portfolios LLC acquired a new stake in Evaxion A/S during the 4th quarter valued at $72,000. Institutional investors and hedge funds own 11.04% of the company’s stock.

Key Stories Impacting Evaxion A/S

Here are the key news stories impacting Evaxion A/S this week:

• Positive Sentiment: Jones Trading initiated coverage with a Buy rating and a $10 price target — a new institutional endorsement that increases visible demand and analyst support. Jones Trading initiates coverage of Evaxion A (EVAX) with buy recommendation
• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and a $16 price target — a high target relative to the current price that supports upside expectations from a well‑known biotech analyst. HC Wainwright Reaffirms Buy Rating for Evaxion A/S (NASDAQ:EVAX)
• Positive Sentiment: Q4 2025 earnings call highlighted strategic partnerships and financial resilience — language that reassures investors on near‑term funding and execution risk. Evaxion AS (EVAX) Q4 2025 Earnings Call Highlights: Strategic Partnerships and Financial Resilience
• Positive Sentiment: Short interest fell ~36% in February (now ~1.1% of float), reducing downward pressure from short sellers and potentially supporting a short‑squeeze dynamic on positive news. No external link
• Negative Sentiment: Lake Street Capital cut its price target to $9, lowering one analyst anchor on valuation and moderating near‑term upside expectations. Lake Street Capital Lowers Evaxion A/S (NASDAQ:EVAX) Price Target to $9.00
• Negative Sentiment: HC Wainwright trimmed several longer‑range EPS forecasts (FY2027–FY2030 updates show lower EPS vs prior estimates), which reduces modeled long‑term earnings and implies the stock’s upside depends on execution and pipeline milestones. (HC Wainwright still maintains a Buy and $16 PT.) No external link

About Evaxion A/S

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.